Histamine H3 receptor
Ensembl | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| UniProt | |||||||||
| RefSeq (mRNA) | |||||||||
| RefSeq (protein) | |||||||||
| Location (UCSC) | Chr 20: 62.21 – 62.22 Mb | Chr 2: 179.74 – 179.75 Mb | |||||||
| PubMed search | [3] | [4] | |||||||
| View/Edit Human | View/Edit Mouse |
Histamine H3 receptors are expressed in the
.The gene sequence for H3 receptors expresses only about 22% and 20% homology with both H1 and H2 receptors respectively.
There is much interest in the histamine H3 receptor as a potential therapeutic target because of its involvement in the neuronal mechanism behind many cognitive disorders and especially its location in the central nervous system.[6][7]
Tissue distribution
- Central nervous system
- Peripheral nervous system
- Heart
- Lungs
- Gastrointestinal tract
- Endothelial cells
Function
Like all histamine receptors, the H3 receptor is a
N-type voltage gated calcium channels
, to reduce action potential mediated influx of calcium and hence reduce neurotransmitter release.
H3 receptors function as presynaptic autoreceptors on histamine-containing neurons.[8]
The diverse expression of H3 receptors throughout the cortex and subcortex indicates its ability to modulate the release of a large number of neurotransmitters.
H3 receptors are thought to play a part in the control of satiety.[9]
Isoforms
There are at least six H3 receptor
isoforms in the human, and more than 20 discovered so far.[10] In rats there have been six H3receptor subtypes identified so far. Mice also have three reported isoforms.[11]
These subtypes all have subtle difference in their pharmacology (and presumably distribution, based on studies in rats) but the exact physiological role of these isoforms is still unclear.
Pharmacology
Agonists
There are currently no therapeutic products acting as selective agonists for H3 receptors, although there are several compounds used as research tools which are reasonably selective agonists. Some examples are:
- (R)-α-methylhistamine
- Cipralisant (initially assessed as H3 antagonist, later found to be an agonist, shows functional selectivity, activating some G-protein coupled pathways but not others)[12]
- Imbutamine (also H4 agonist)
- Immepip
- Imetit
- Immethridine
- Methimepip
- Proxyfan (complex functional selectivity; partial agonist effects on cAMP inhibition and MAPK activity, antagonist on histamine release, and inverse agonist on arachidonic acid release)
Antagonists
These include:[13]
- A-304121 (No tolerance formation, silent antagonist)[14]
- A-349,821[15]
- ABT-239
- Betahistine (also weak H1 agonist)
- Burimamide (also weak H2 antagonist)
- Ciproxifan
- Clobenpropit (also H4 antagonist)
- Conessine
- Failproxifan[citation needed] (No tolerance formation)[citation needed]
- Impentamine
- Iodophenpropit
- Irdabisant
- Pitolisant
- Thioperamide (also H4 antagonist)
- VUF-5681 (4-[3-(1H-Imidazol-4-yl)propyl]piperidine)
Therapeutic potential
The H3-receptor is a promising potential therapeutical target for many (cognitive) disorders that are caused by a histaminergic H3R dysfunction, because it is linked to the central nervous system and its regulation of other neurotransmitters.[6][16][17] Examples of such disorders are: sleep disorders (including narcolepsy), Tourette syndrome, Parkinson, OCD, ADHD, ASS and drug addictions.[6][17]
This receptor has been proposed as a target for treating sleep disorders.[18] The receptor has also been proposed as a target for treating neuropathic pain.[19]
Because of its ability to modulate other neurotransmitters, H3 receptor
There is also evidence that the H3-receptor plays an important role in Tourette syndrome.[21] Mouse-models and other research demonstrated that reducing histamine concentration in the H3R causes tics, but adding histamine in the striatum decreases the symptoms.[22][23][24] The interaction between histamine (H3-receptor) and dopamine as well as other neurotransmitters is an important underlying mechanism behind the disorder.[25]
History
- 1983 The H3 receptor is pharmacologically identified.[26]
- 1988 H3 receptor found to mediate inhibition of serotonin release in rat brain cortex.[27]
- 1997 H3 receptors shown to modulate ischemic norepinephrine release in animals.[28]
- 1999 H3 receptor cloned[29]
- 2000 H3 receptors called "new frontier in myocardial ischemia"[30]
- 2002 H3(-/-) mice (mice that do not have this receptor)[31]
See also
- Antihistamine – histamine receptor antagonists
- H3-receptor antagonist
- Histamine H1-receptor
- Histamine H2-receptor
- Histamine H4-receptor
References
- ^ a b c GRCh38: Ensembl release 89: ENSG00000101180 – Ensembl, May 2017
- ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000039059 – Ensembl, May 2017
- ^ "Human PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- ^ "Mouse PubMed Reference:". National Center for Biotechnology Information, U.S. National Library of Medicine.
- PMID 2172771.
- ^ a b c Rapanelli, Maximiliano. “The Magnificent Two: Histamine and the H3 Receptor as Key Modulators of Striatal Circuitry.” Progress in Neuro-Psychopharmacology and Biological Psychiatry 73 (February 2017): 36–40
- ^ a b Sadek, Bassem, Ali Saad, Adel Sadeq, Fakhreya Jalal, and Holger Stark. “Histamine H3 Receptor as a Potential Target for Cognitive Symptoms in Neuropsychiatric Diseases.” Behavioural Brain Research 312 (October 2016): 415–430
- ^ "InterPro: IPR003980 Histamine H3 receptor". InterPro. European Bioinformatics Institute.
- PMID 11459437.
- S2CID 9630188.
- S2CID 29078902.
- S2CID 20470970.
- PMID 10215700.
- PMID 16730751.
- PMID 15294456.
- ^ Bolam, J. Paul, and Tommas J. Ellender. “Histamine and the Striatum.” Neuropharmacology 106 (July 2016): 74–84
- ^ a b Sadek, Bassem, Ali Saad, Adel Sadeq, Fakhreya Jalal, and Holger Stark. “Histamine H3 Receptor as a Potential Target for Cognitive Symptoms in Neuropsychiatric Diseases.” Behavioural Brain Research 312 (October 2016): 415–430
- PMID 15530639.
- S2CID 43724064.
- S2CID 32781560.
- ^ Cox, Joanna H., Stefano Seri, and Andrea E. Cavanna. “Histaminergic Modulation in Tourette Syndrome.” Expert Opinion on Orphan Drugs 4, no. 2 (February 1, 2016): 205–213
- ^ Bolam, J. Paul, and Tommas J. Ellender. “Histamine and the Striatum.” Neuropharmacology 106 (July 2016): 74–84
- ^ Rapanelli, Maximiliano, Luciana Frick, Haruhiko Bito, and Christopher Pittenger. “Histamine Modulation of the Basal Ganglia Circuitry in the Development of Pathological Grooming.” Proceedings of the National Academy of Sciences (June 5, 2017): 6599–6604
- ^ Rapanelli, Maximiliano, and Christopher Pittenger. “Histamine and Histamine Receptors in Tourette Syndrome and Other Neuropsychiatric Conditions.” Neuropharmacology 106 (July 2016): 85–90
- ^ Baldan, Lissandra Castellan, Kyle A. Williams, Jean-Dominique Gallezot, Vladimir Pogorelov, Maximiliano Rapanelli, Michael Crowley, George M. Anderson, et al. “Histidine Decarboxylase Deficiency Causes Tourette Syndrome: Parallel Findings in Humans and Mice.” Neuron 81, no. 1 (January 8, 2014): 77–90
- S2CID 4302564.
- S2CID 24168192.
- PMID 9353362.
- S2CID 25542667.
- PMID 10688593.
- S2CID 25583387.
Further reading
- Hill SJ, Ganellin CR, Timmerman H, Schwartz JC, Shankley NP, Young JM, Schunack W, Levi R, Haas HL (Sep 1997). "International Union of Pharmacology. XIII. Classification of histamine receptors". Pharmacological Reviews. 49 (3): 253–78. PMID 9311023.
- Malinowska B, Godlewski G, Schlicker E (Jun 1998). "Histamine H3 receptors--general characterization and their function in the cardiovascular system". Journal of Physiology and Pharmacology. 49 (2): 191–211. PMID 9670104.
- Leurs R, Hoffmann M, Wieland K, Timmerman H (Jan 2000). "H3 receptor gene is cloned at last". Trends in Pharmacological Sciences. 21 (1): 11–2. PMID 10637648.
- Leurs R, Bakker RA, Timmerman H, de Esch IJ (Feb 2005). "The histamine H3 receptor: from gene cloning to H3 receptor drugs". Nature Reviews. Drug Discovery. 4 (2): 107–20. S2CID 32781560.
- Esbenshade TA, Fox GB, Cowart MD (Apr 2006). "Histamine H3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders". Molecular Interventions. 6 (2): 77–88, 59. PMID 16565470.
- Lovenberg TW, Roland BL, Wilson SJ, Jiang X, Pyati J, Huvar A, Jackson MR, Erlander MG (Jun 1999). "Cloning and functional expression of the human histamine H3 receptor". Molecular Pharmacology. 55 (6): 1101–7. S2CID 25542667.
- Nakamura T, Itadani H, Hidaka Y, Ohta M, Tanaka K (Dec 2000). "Molecular cloning and characterization of a new human histamine receptor, HH4R". Biochemical and Biophysical Research Communications. 279 (2): 615–20. PMID 11118334.
- Cogé F, Guénin SP, Audinot V, Renouard-Try A, Beauverger P, Macia C, Ouvry C, Nagel N, Rique H, Boutin JA, Galizzi JP (Apr 2001). "Genomic organization and characterization of splice variants of the human histamine H3 receptor". The Biochemical Journal. 355 (Pt 2): 279–88. PMID 11284713.
- Silver RB, Poonwasi KS, Seyedi N, Wilson SJ, Lovenberg TW, Levi R (Jan 2002). "Decreased intracellular calcium mediates the histamine H3-receptor-induced attenuation of norepinephrine exocytosis from cardiac sympathetic nerve endings". Proceedings of the National Academy of Sciences of the United States of America. 99 (1): 501–6. PMID 11752397.
- Wiedemann P, Bönisch H, Oerters F, Brüss M (Apr 2002). "Structure of the human histamine H3 receptor gene (HRH3) and identification of naturally occurring variations". Journal of Neural Transmission. 109 (4): 443–53. S2CID 32434148.
- Wellendorph P, Goodman MW, Burstein ES, Nash NR, Brann MR, Weiner DM (Jun 2002). "Molecular cloning and pharmacology of functionally distinct isoforms of the human histamine H(3) receptor". Neuropharmacology. 42 (7): 929–40. S2CID 54326678.
- Lozeva V, Tuomisto L, Tarhanen J, Butterworth RF (Oct 2003). "Increased concentrations of histamine and its metabolite, tele-methylhistamine and down-regulation of histamine H3 receptor sites in autopsied brain tissue from cirrhotic patients who died in hepatic coma". Journal of Hepatology. 39 (4): 522–7. PMID 12971961.
- Lippert U, Artuc M, Grützkau A, Babina M, Guhl S, Haase I, Blaschke V, Zachmann K, Knosalla M, Middel P, Krüger-Krasagakis S, Henz BM (Jul 2004). "Human skin mast cells express H2 and H4, but not H3 receptors". The Journal of Investigative Dermatology. 123 (1): 116–23. PMID 15191551.
External links
- "Histamine Receptors: H3". IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Archived from the original on 2013-12-25. Retrieved 2006-07-20.
- H3+receptors at the U.S. National Library of Medicine Medical Subject Headings (MeSH)